- ISIN
- US68237Q1040
- CUSIP
- 682160106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 18, 2022
Highlights
- Market Cap
- $276.14K
- Enterprise Value
- -$2.88M
- EPS (TTM)
- -$3.30
- Total Revenue (TTM)
- $735.20K
- Gross Profit (TTM)
- $585.43K
- EBITDA (TTM)
- -$22.13M
- Year Range
- $0.67 - $209.50
- ROA (TTM)
- -65.41%
- ROE (TTM)
- -82.59%
- Avg. Volume (1M)
- 681K
- Avg. Volume Value (1M)
- $639.34K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ONCO Performance Chart
Onconetix Inc (ONCO) is down 98.9% since the beginning of the year. At $1 per share, ONCO is trading 99.6% below its 52-week high of $209.
Loading charts...
Compare this symbol against anything
Returns By Period
Onconetix Inc (ONCO) has returned -98.94% so far this year and -99.52% over the past 12 months.
Onconetix Inc
- 1D
- 5.12%
- 1M
- -13.48%
- 6M
- -98.84%
- YTD
- -98.94%
- 1Y
- -99.52%
- 3Y*
- -98.35%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -97.35%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
ONCO Monthly Returns History
Based on dividend-adjusted daily data since Feb 18, 2022, ONCO's average daily return is -0.75%, while the average monthly return is -17.73%.
Historically, 20% of months were positive and 80% were negative. The best month was May 2024 with a return of +76.2%, while the worst month was Apr 2022 at -93.7%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 11 months.
On a daily basis, ONCO closed higher 38% of trading days. The best single day was Aug 17, 2022 with a return of +199.6%, while the worst single day was Apr 7, 2022 at -82.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.97% | -52.89% | -55.46% | -53.39% | -82.72% | -5.83% | -26.84% | -98.94% | |||||
| 2025 | -13.62% | -54.54% | -68.47% | -6.28% | 6.70% | -28.05% | -25.37% | -17.70% | 6.14% | 9.00% | -17.99% | -43.88% | -97.09% |
| 2024 | -3.48% | -10.52% | -9.94% | -23.96% | 76.17% | -18.95% | -7.30% | -12.39% | -4.27% | -44.42% | -76.12% | -8.70% | -92.05% |
| 2023 | 11.82% | -4.88% | -8.55% | 0.00% | -24.76% | 40.36% | 0.00% | -29.29% | -35.97% | -23.77% | -38.49% | -17.47% | -82.00% |
| 2022 | -0.80% | 13.91% | -93.65% | 22.84% | -51.70% | 57.28% | -5.97% | -45.71% | -27.49% | 2.42% | -13.39% | -97.80% |
Benchmark Metrics
Onconetix Inc has an annualized alpha of -86.60%, beta of 0.80, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 18, 2022.
- This stock participated in 291.84% of S&P 500 Index downside but only -145.31% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -86.60%
- Beta
- 0.80
- R²
- 0.00
- Upside Capture
- -145.31%
- Downside Capture
- 291.84%
Return for Risk
Risk / Return Rank
ONCO ranks 5 for risk / return — above 5% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Onconetix Inc (ONCO) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ONCO | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.06 | ||
| Sortino ratioReturn per unit of downside risk | -5.05 | ||
| Omega ratioGain probability vs. loss probability | 0.62 | 1.25 | -0.64 |
| Calmar ratioReturn relative to maximum drawdown | -1.00 | 2.00 | -3.00 |
| Martin ratioReturn relative to average drawdown | -1.41 | 8.49 | -9.90 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Onconetix Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Onconetix Inc was 100.00%, occurring on Jul 29, 2026. The portfolio has not yet recovered.
The current Onconetix Inc drawdown is 100.00%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-100.00%Jul 2026 | 4y 4mo | — | 4y 4moMar 2022 - now | — |
-25.43%Feb 2022 | 2d | 6d | 8dFeb 2022 - Mar 2022 | Bear market2022 |
-4.85%Mar 2022 | 3d | 1d | 4dMar 2022 - Mar 2022 | Bear market2022 |
-3.35%Mar 2022 | 4d | 2d | 6dMar 2022 - Mar 2022 | Bear market2022 |
Drawdown Indicators
| ONCO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -99.64% | -9.10% | -90.54% |
Max Drawdown (3Y)Largest decline over 3 years | -100.00% | -18.90% | -81.10% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -100.00% | -1.58% | -98.42% |
Average DrawdownAverage peak-to-trough decline | -96.49% | -10.70% | -85.79% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 70.68% | 2.14% | +68.54% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Onconetix Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Onconetix Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ONCO relative to other companies in the Biotechnology industry. Currently, ONCO has a P/S ratio of 3.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ONCO in comparison with other companies in the Biotechnology industry. Currently, ONCO has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ONCO
Add Onconetix Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ONCO